News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MarketBeat Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Century Therapeutics (NASDAQ:IPSC) reported a quarterly loss of $0.17 per share, missing analysts' estimates by $0.06. Following the earnings release, shares declined by 1.9% to $2.02, while the company maintains a consensus "Hold" rating and an average price target of $4.75 from analysts. Institutional …
Century Therapeutics (NASDAQ: IPSC) announced its second-quarter 2026 financial results, reporting a net loss of $34.6 million. The company has aligned with the FDA on its trial plan for CNTY-813, an iPSC-derived islet replacement therapy for type 1 diabetes, keeping its IND filing on …
This article announces that Century Therapeutics Inc. filed a Form 8K on August 12. It briefly mentions the company and its stock symbol (IPSC) and includes boilerplate market data and popular news unrelated to the Form 8K.
Century Therapeutics (IPSC) reported a Q2 2026 net loss of $34.6 million, an increase from $32.5 million in Q2 2025. Despite the loss, the company has a strong cash runway extending into Q1 2029 with $197.2 million in cash, cash equivalents, and investments. The …
* Century Therapeutics press release [https://seekingalpha.com/pr/20616368-century-therapeutics-reports-second-quarter-2026-financial-results-and-business-updates] (IPSC [https://seekingalpha.com/symbol/IPSC]): Q2 GAAP EPS of -$0.17 misses by $0.05. * Cash runway into 1Q 2029 with cash, cash equivalents, and investments of $197.2 million as of June 30, 2026 MORE ON CENTURY THERAPEUTICS * Century: 'Hold' Based …
Century Therapeutics reported a Q2 2026 net loss of $34.6 million, bringing its six-month loss to $56.2 million, a significant swing from a $44.0 million net income in the prior year due to the termination of a collaboration with Bristol-Myers Squibb. Despite the loss …
Century Therapeutics, Inc. reported its Q2 2026 financial results, showing $0 revenue and a net loss of $34.6M, or diluted EPS of $(0.17). The company highlighted pipeline progress with IND-enabling studies for CNTY-813, continued platform development, and operational milestones in manufacturing. Cost realignments and …
Century Therapeutics (NASDAQ: IPSC) is projected to announce its Q2 2026 earnings before market open on Thursday, August 13th, with analysts expecting a loss of $0.11 per share and revenue of $2.17 million. The company's stock has declined 2.5% and institutional investors hold about …
Century Therapeutics' SVP of Finance & Operations, Douglas Carr, automatically sold 275 shares of common stock at $1.977 per share on August 3, 2026. This sale was not discretionary but was executed to cover tax withholding obligations associated with the vesting of restricted stock …
Seven Fleet Capital Management LP has acquired 4.35 million shares of Century Therapeutics, Inc. (NASDAQ:IPSC), valued at approximately $9.8 million, making it their fourth-largest holding. This investment represents a 2.41% stake in Century Therapeutics, with other institutional investors like AQR Capital and Goldman Sachs …
Century Therapeutics Inc is expected to report an earnings loss of 11 cents per share. This information comes from a Refinitiv earnings preview. The full article provides further details on these expectations.
This article provides a financial health analysis of Century Therapeutics Inc (IPSC), indicating a current financial score of 8.25, ranking 50 out of 384 in its industry. Although its financial status is stable and operating efficiency is high, the company reported a 100.00% year-over-year …
TradingKey's analysis of Century Therapeutics Inc (IPSC) indicates healthy fundamentals, high growth potential, and a fairly valued assessment within the Biotechnology & Medical Research industry. The company has strong institutional ownership and multiple "Buy" ratings from analysts with a high price target. Despite recent …
This article provides a detailed cash flow statement for Century Therapeutics Inc (IPSC), including operating, investing, and financing cash flow data on both a quarterly and annual basis. It also features frequently asked questions (FAQs) defining various cash flow metrics and their significance for …
Century Therapeutics, Inc. (NASDAQ: IPSC) reported a significant increase in its revenue, reaching $109.16 million USD last year. The primary driver for this growth was its "Allogeneic Cell Therapies" segment, which also contributed the majority of its revenue from the United States. This marks …
This article provides a risk assessment for Century Therapeutics Inc (IPSC), highlighting its beta, volatility, and various return metrics. The company's risk score is 2.04, placing it 242nd out of 386 in the Biotechnology & Medical Research industry. It details key performance indicators such …
This article details the institutional confidence score for Century Therapeutics Inc (IPSC), which stands at 5.00, placing it 132nd within the Biotechnology & Medical Research industry. Institutional shareholding has seen a significant quarter-over-quarter increase of 64.36%, with the largest shareholder being Steven Cohen. The …
Century Therapeutics (IPSC) stock is trading steadily following updates on its clinical pipeline and cash runway. The company reported a narrowing operating loss and net loss for fiscal 2025, with revenue increasing to $3.1 million. With $280 million in cash and investments, Century Therapeutics …
Century Therapeutics (IPSC) stock is trading near recent lows as the company faces continued net losses and significant cash burn, despite a slight narrowing of its net loss in fiscal 2023. The biotech firm and its iPSC-derived cell therapy pipeline require substantial R&D investment, …
Century Therapeutics (NASDAQ:IPSC), despite its stock soaring by 263% over the last year, is an unprofitable company. The company had a cash runway of approximately 17 months as of March 2026, with a cash burn of US$95 million against reserves of US$135 million. While …
Search by ticker symbol or company name and select a result to open its chart.